Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review
Prostate cancer is a disease of older adults that has undergone a significant therapeutic paradigm shift in the last decade with the emergence of novel androgen receptor pathway inhibitors (ARPis). One of the more commonly used ARPis is enzalutamide. This drug, along with darolutamide and apalutamid...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359221149887 |
| _version_ | 1797938283734368256 |
|---|---|
| author | Nabiel Mir Olivia Burke Samuel Yates Tanujaa Rajasekaran Johan Chan Russell Szmulewitz Ravindran Kanesvaran |
| author_facet | Nabiel Mir Olivia Burke Samuel Yates Tanujaa Rajasekaran Johan Chan Russell Szmulewitz Ravindran Kanesvaran |
| author_sort | Nabiel Mir |
| collection | DOAJ |
| description | Prostate cancer is a disease of older adults that has undergone a significant therapeutic paradigm shift in the last decade with the emergence of novel androgen receptor pathway inhibitors (ARPis). One of the more commonly used ARPis is enzalutamide. This drug, along with darolutamide and apalutamide, initially received approvals in the metastatic castrate-resistant prostate cancer setting but is now utilized frequently in the metastatic castrate-sensitive and non-metastatic castration-resistant settings. Landmark phase III data illustrating ARPi efficacy in older adults are limited to those with excellent performance status. However, its role in unfit older prostate cancer patients remains to be explored in the context of a narrative review. This first-of-its-kind drug review aims to shed light on the most up-to-date evidence behind the unique toxicity profile of ARPis in the context of geriatric vulnerabilities such as cognitive and functional impairment, along with potential solutions and supporting evidence that exists to circumvent these issues in the vulnerable older adult. |
| first_indexed | 2024-04-10T18:58:17Z |
| format | Article |
| id | doaj.art-c538571d900f4d0588eaad6fbdf03706 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-10T18:58:17Z |
| publishDate | 2023-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-c538571d900f4d0588eaad6fbdf037062023-01-31T16:04:00ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-01-011510.1177/17588359221149887Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug reviewNabiel MirOlivia BurkeSamuel YatesTanujaa RajasekaranJohan ChanRussell SzmulewitzRavindran KanesvaranProstate cancer is a disease of older adults that has undergone a significant therapeutic paradigm shift in the last decade with the emergence of novel androgen receptor pathway inhibitors (ARPis). One of the more commonly used ARPis is enzalutamide. This drug, along with darolutamide and apalutamide, initially received approvals in the metastatic castrate-resistant prostate cancer setting but is now utilized frequently in the metastatic castrate-sensitive and non-metastatic castration-resistant settings. Landmark phase III data illustrating ARPi efficacy in older adults are limited to those with excellent performance status. However, its role in unfit older prostate cancer patients remains to be explored in the context of a narrative review. This first-of-its-kind drug review aims to shed light on the most up-to-date evidence behind the unique toxicity profile of ARPis in the context of geriatric vulnerabilities such as cognitive and functional impairment, along with potential solutions and supporting evidence that exists to circumvent these issues in the vulnerable older adult.https://doi.org/10.1177/17588359221149887 |
| spellingShingle | Nabiel Mir Olivia Burke Samuel Yates Tanujaa Rajasekaran Johan Chan Russell Szmulewitz Ravindran Kanesvaran Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review Therapeutic Advances in Medical Oncology |
| title | Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review |
| title_full | Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review |
| title_fullStr | Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review |
| title_full_unstemmed | Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review |
| title_short | Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review |
| title_sort | androgen receptor pathway inhibitors prostate cancer and older adults a global young international society of geriatric oncology drug review |
| url | https://doi.org/10.1177/17588359221149887 |
| work_keys_str_mv | AT nabielmir androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT oliviaburke androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT samuelyates androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT tanujaarajasekaran androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT johanchan androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT russellszmulewitz androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview AT ravindrankanesvaran androgenreceptorpathwayinhibitorsprostatecancerandolderadultsaglobalyounginternationalsocietyofgeriatriconcologydrugreview |